Premaitha Share Discussion Threads

[twix386] 12/5/2017 16:10

Strange whenever mouse speaks his views are completely disowned by the markets reaction.Just a knocker with a gripe imv

[hjb1] 12/5/2017 15:37

ha ha! mouse, you are a sad git!! get a life ffs!!

[michaelmouse] 12/5/2017 15:36

I've had a stab at re-wording the RNS:-

"Dear shareholders, a valued Swiss customer couldn't stump up the £750,000 they owed us, so we've made them bankrupt, and will spend considerable time, money and effort now trying to recover the debt. Not to worry, we've got a great opportunity to spend additional time, money and effort trying to deal directly with their customers instead. I don't know why we bothered with this customer in the first place really when we can clearly do it all ourselves and not p*ss £750,000 up the wall."

How's that?

Aimho of course.

[on target] 12/5/2017 15:17

Probably best to read the full RNS rather than part of one sentence?

[michaelmouse] 12/5/2017 15:14

Off target - "Hmmm looks like rather good news. Has the market missed this RNS?"

LOL

"While it is anticipated that a full provision will be required in the accounts to 31 March 2017 for the outstanding debt owed to Premaitha by Genoma of approximately GBP750,000"

Great news. A company that makes massive losses, burnt through almost £7m last year and a further £3.5m by the interim period this year has got to make a £750,000 provision in this year's results with on guarantee that they'll recover any of the debt.

I'll have what you're drinking :)

[twodegrees] 12/5/2017 14:52

On Target, the last week the share has been rising again, maybe they did not miss it...or the fact that Rns has just come out, maybe they had no idea, but it is climbing nicely this aft.

[on target] 12/5/2017 14:47

Hmmm looks like rather good news. Has the market missed this RNS?

[twodegrees] 12/5/2017 14:41

Well it seems like the legal people who work for premaitha are able to present a case and win. Does this bode well for the other cases waiting to be resolved.

[humphries1] 12/5/2017 14:27

12 May 2017

Premaitha Health plc

Update Re. Swiss Customer

Manchester, UK - 12 May 2017: Premaitha Health plc (AIM: NIPT, "Premaitha" or the "Company"), a leading international molecular diagnostics group focused on prenatal testing, announces that the Company's application for its Swiss customer, Genoma SA ("Genoma"), to be placed into bankruptcy for non-payment of debts has been successful (the "Ruling").

As previously announced in the Company's interim results (see RNS announcement on 21 December 2016), Genoma had been experiencing financial difficulties. On 21 April 2017, Genoma's parent company, Esperite (Euronext: ESP), announced it had concluded a fundraising exercise. These funds have not, apparently, been made available to Genoma and, following proceedings instigated by Premaitha in the Swiss courts, the official Swiss commercial register has today confirmed the Ruling in favour of Premaitha's application.

While it is anticipated that a full provision will be required in the accounts to 31 March 2017 for the outstanding debt owed to Premaitha by Genoma of approximately GBP750,000, the Company will now vigorously pursue all options to recover the debt or equivalent assets and will provide further updates in due course.

Furthermore, Premaitha believes Genoma's bankruptcy presents a commercial opportunity to sell to the sizeable NIPT customer base which had been built up in Switzerland and certain other European countries by Genoma when they were using the IONA(R) test from Premaitha, but which Genoma had recently been converting to their own in-house successor product. Premaitha will target these customers directly and through its recently expanded distribution network.

Additionally, Genoma's bankruptcy simplifies the ongoing UK intellectual property litigation against Premaitha as there will no longer be a parallel action in Switzerland.

The Company understands that Genoma has a short period in which to appeal the Ruling and will make a further announcement if applicable.

Dr Stephen Little, CEO, commented: "The Swiss court ruling to place Genoma into bankruptcy is a positive development in an otherwise unfortunate situation as it will now accelerate our pursuit of the recovery of this debt in various possible forms from Esperite or the official receiver. Moreover, there is a commercial opportunity now to secure and build on the NIPT customer base they had built using the IONA(R) test both within and outside of Switzerland."

[the monkster] 09/5/2017 08:14

this has been a real 5hitter and looks like it will continue to be so

[christopher logsdon] 02/5/2017 09:20

I'm very annoyed my first buy was at 20p

[forcemode] 02/5/2017 03:23

Re "imminent" Trading Statement - I see that last year's was issued on 11th April so this years is a little late! Does anyone know what the procedure is for issuing TSs? Are they compulsory and, if so, when do they have to be issued? TIA

[ngen yap] 24/4/2017 22:52

I am sure many are, as am I, annoyed with drift back to 10p but we should look at volume - been so light to warrant the drops! Let's see what they say in trading update expected imminently. All the best.

[hjb1] 24/4/2017 09:52

good, hopefully they will pay their debts first!

[ngen yap] 24/4/2017 07:59

Esperite financing of up to €13m approved on Friday.

[gooosed] 22/4/2017 08:29

timojelly - approx. 3 months to writ case victory/settlement/loss. There have been a few large-ish (200k) buys popping up on a fairly regular basis - someone perhaps merely taking a punt or maybe confident of a positive resolution. Who knows but a few twists and turns to come I suspect before judgement day.

[hjb1] 21/4/2017 17:03

more like 18p !!

[the monkster] 21/4/2017 16:41

yes, not long till we hit 8p

[timojelly] 20/4/2017 12:52

Time marching on for the big showdown

[timojelly] 31/3/2017 16:19

Another 2mill into the coffers

[timojelly] 24/3/2017 10:29

First ever blood tests to diagnose cancer 'could be ready in one year'hTTps://www.independent.co.uk/life-style/health-and-families/health-news/cancer-blood-test-university-of-california-jasmine-zhou-dna-tumour-samples-computer-program-a7646956.html?amp